Cargando…
837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis
BACKGROUND: Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles necessitating evaluation of additional therapeutic options. METHODS: Patients with coccidioidomycosis who received Isavuconaz...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678949/ http://dx.doi.org/10.1093/ofid/ofad500.882 |
_version_ | 1785150477959168000 |
---|---|
author | Heidari, Arash Sharma, Rupam Shakir, Qusai Shah, Madiha Donnelly, Monica Reynolds, Trina Trigg, Kate Joliff, Jeff Kuran, Rasha Johnson, Royce H Thompson, George R |
author_facet | Heidari, Arash Sharma, Rupam Shakir, Qusai Shah, Madiha Donnelly, Monica Reynolds, Trina Trigg, Kate Joliff, Jeff Kuran, Rasha Johnson, Royce H Thompson, George R |
author_sort | Heidari, Arash |
collection | PubMed |
description | BACKGROUND: Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles necessitating evaluation of additional therapeutic options. METHODS: Patients with coccidioidomycosis who received Isavuconazole were identified by cross-indexing ICD-9 and ICD-10 codes from patients and data abstracted. Responses to Isavuconazole therapy were measured using a modified Mycoses Study Group Coccidioidomycosis Scoring system as described previously. RESULTS: 82 patients met the criteria for inclusion. Over half of the patient exhibited pulmonary involvement 45/82 (55%), although meningitis 32/82 (39%), bone and joint disease 14/82 (17%) and skin/soft tissue infection 7/82 (9%) were also seen. The majority of patients experienced a decrease in their MSG score following initiation of Isavuconazole therapy (median MSG score change across all patient groups 7 → 2, p< 0.0001). Overall improvement was noted in 58/82 (71%) patients, while no change was observed in 19/82 (23%) and 5/82 (6%) who were unresponsive to antifungal changes. CONCLUSION: Isavuconazole demonstrated efficacy in the majority of patients treated, with failures observed only in a subgroup of patients with coccidioidal meningitis. DISCLOSURES: Rupam Sharma, PGY-1/MD, Astellas: Grant/Research Support George R. Thompson, III, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|Cidara: Advisor/Consultant|Cidara: Grant/Research Support|F2G: Advisor/Consultant|F2G: Grant/Research Support|Mayne: Advisor/Consultant|Mayne: Grant/Research Support|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support |
format | Online Article Text |
id | pubmed-10678949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106789492023-11-27 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis Heidari, Arash Sharma, Rupam Shakir, Qusai Shah, Madiha Donnelly, Monica Reynolds, Trina Trigg, Kate Joliff, Jeff Kuran, Rasha Johnson, Royce H Thompson, George R Open Forum Infect Dis Abstract BACKGROUND: Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles necessitating evaluation of additional therapeutic options. METHODS: Patients with coccidioidomycosis who received Isavuconazole were identified by cross-indexing ICD-9 and ICD-10 codes from patients and data abstracted. Responses to Isavuconazole therapy were measured using a modified Mycoses Study Group Coccidioidomycosis Scoring system as described previously. RESULTS: 82 patients met the criteria for inclusion. Over half of the patient exhibited pulmonary involvement 45/82 (55%), although meningitis 32/82 (39%), bone and joint disease 14/82 (17%) and skin/soft tissue infection 7/82 (9%) were also seen. The majority of patients experienced a decrease in their MSG score following initiation of Isavuconazole therapy (median MSG score change across all patient groups 7 → 2, p< 0.0001). Overall improvement was noted in 58/82 (71%) patients, while no change was observed in 19/82 (23%) and 5/82 (6%) who were unresponsive to antifungal changes. CONCLUSION: Isavuconazole demonstrated efficacy in the majority of patients treated, with failures observed only in a subgroup of patients with coccidioidal meningitis. DISCLOSURES: Rupam Sharma, PGY-1/MD, Astellas: Grant/Research Support George R. Thompson, III, MD, Astellas: Advisor/Consultant|Astellas: Grant/Research Support|Cidara: Advisor/Consultant|Cidara: Grant/Research Support|F2G: Advisor/Consultant|F2G: Grant/Research Support|Mayne: Advisor/Consultant|Mayne: Grant/Research Support|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10678949/ http://dx.doi.org/10.1093/ofid/ofad500.882 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Heidari, Arash Sharma, Rupam Shakir, Qusai Shah, Madiha Donnelly, Monica Reynolds, Trina Trigg, Kate Joliff, Jeff Kuran, Rasha Johnson, Royce H Thompson, George R 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title | 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title_full | 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title_fullStr | 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title_full_unstemmed | 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title_short | 837. Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis |
title_sort | 837. isavuconazole in the treatment of chronic forms of coccidioidomycosis |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678949/ http://dx.doi.org/10.1093/ofid/ofad500.882 |
work_keys_str_mv | AT heidariarash 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT sharmarupam 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT shakirqusai 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT shahmadiha 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT donnellymonica 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT reynoldstrina 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT triggkate 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT joliffjeff 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT kuranrasha 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT johnsonroyceh 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis AT thompsongeorger 837isavuconazoleinthetreatmentofchronicformsofcoccidioidomycosis |